On January 3, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the Board") of Crinetics Pharmaceuticals, Inc. (the Company"), and pursuant to the amended and restated bylaws of the Company, the Board approved an increase in its authorized size from six members to seven members and appointed Rog rio Vivaldi Coelho, M.D., M.B.A. to fill the vacancy created by such increase and serve as a Class I director, with an initial term expiring at the Company's 2022 annual meeting of stockholders. In connection with his appointment to the Board, Dr. Vivaldi was also appointed to the Audit Committee of the Board.